Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review

A systematic review of the literature was conducted to determine the estimates of and definitions for human papillomavirus (HPV) persistence in women following treatment of cervical intra‐epithelial neoplasia (CIN). A total of 45 studies presented data on post‐treatment HPV persistence among 6,106 women. Most studies assessed HPV persistence after loop excision (42%), followed by conization (7%), cryotherapy (11%), laser treatment (4%), interferon‐alpha, therapeutic vaccination, and photodynamic therapy (2% each) and mixed treatment (38%). Baseline HPV testing was conducted before or at treatment for most studies (96%). Follow‐up HPV testing ranged from 1.5 to 80 months after baseline. Median HPV persistence tended to decrease with increasing follow‐up time, declining from 27% at 3 months after treatment to 21% at 6 months, 15% at 12 months, and 10% at 24 months. Post‐treatment HPV persistence estimates varied widely and were influenced by patient age, HPV‐type, detection method, treatment method, and minimum HPV post‐treatment testing interval. Loop excision and conization appeared to outperform cryotherapy procedures in terms of their ability to clear HPV infection. This systematic review provides evidence for the substantial heterogeneity in post‐treatment HPV DNA testing practices and persistence estimates.

[1]  P. Hillemanns,et al.  HPV testing in the context of post-treatment follow up (test of cure). , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[2]  L. Mariani,et al.  HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions , 2016, Journal of Cancer.

[3]  Zhaoning Duan,et al.  Analysis of Residual/Recurrent Disease and Its Risk Factors after Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia , 2015, Gynecologic and Obstetric Investigation.

[4]  L. Mariani,et al.  Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma , 2015, Ecancermedicalscience.

[5]  A. Lopes,et al.  Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. , 2015, Cochrane Database of Systematic Reviews.

[6]  C. Togrul,et al.  Risk factors for human papillomavirus persistence among women undergoing cold‐knife conization for treatment of high‐grade cervical intraepithelial neoplasia , 2014, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[7]  Jennifer S. Smith,et al.  The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. , 2014, Gynecologic oncology.

[8]  M. Hudgens,et al.  Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta‐analysis , 2013, International journal of cancer.

[9]  Robert P Berkowitz,et al.  2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. , 2013, Obstetrics and gynecology.

[10]  A. Ryu,et al.  Early human papillomavirus testing predicts residual/recurrent disease after LEEP , 2012, Journal of gynecologic oncology.

[11]  M. Sherman,et al.  Long‐term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment , 2012, International journal of cancer.

[12]  A. Fiander,et al.  Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[13]  W. Silny,et al.  Evaluation of HPV DNA HR assay in females as a marker of recurrent disease following treatment of cervical intraepithelial neoplasia. , 2011, Ginekologia polska.

[14]  J. Heymans,et al.  Type‐specific HPV geno‐typing improves detection of recurrent high‐grade cervical neoplasia after conisation , 2011, International journal of cancer.

[15]  P. Bistoletti Clearance of human papillomavirus in women treated for cervical dysplasia. , 2011, Obstetrics and gynecology.

[16]  N. Dogan,et al.  The role of HPV DNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure , 2011, Archives of Gynecology and Obstetrics.

[17]  J. Nam,et al.  Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. , 2010, American journal of obstetrics and gynecology.

[18]  J. Thinkhamrop,et al.  Cryotherapy for HPV clearance in women with biopsy‐confirmed cervical low‐grade squamous intraepithelial lesions , 2010, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  P. Hillemanns,et al.  The significance of HPV in the follow-up period after treatment for CIN. , 2010, European journal of gynaecological oncology.

[20]  N. Surico,et al.  Role of HPV testing in the follow-up of women treated for cervical dysplasia , 2010, Archives of Gynecology and Obstetrics.

[21]  I. Bezircioğlu,et al.  Residual and recurrent disease rates following LEEP treatment in high-grade cervical intraepithelial lesions , 2010, Archives of Gynecology and Obstetrics.

[22]  B. Johansson,et al.  Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. , 2009, American journal of obstetrics and gynecology.

[23]  D. Bae,et al.  Factors associated with HPV persistence after conization in patients with negative margins. , 2009, Journal of gynecologic oncology.

[24]  C. Meijer,et al.  Post‐treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease , 2009, International journal of cancer.

[25]  M. Temmerman,et al.  Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia , 2009, Cytopathology : official journal of the British Society for Clinical Cytology.

[26]  C. Poole,et al.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[27]  G. Scarselli,et al.  PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes after laser CO2 conization for high-grade cervical intraepithelial neoplasia. , 2008, Gynecologic oncology.

[28]  S. Dong,et al.  The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. , 2008, Gynecologic oncology.

[29]  S. Vansteelandt,et al.  Natural history and clearance of HPV after treatment of precancerous cervical lesions , 2008, Histopathology.

[30]  M. Fambrini,et al.  Prognostic significance of high-risk HPV persistence after laser CO2 conization for high-grade CIN: a prospective clinical study. , 2008, European journal of gynaecological oncology.

[31]  S. Namkoong,et al.  Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure , 2007, International Journal of Gynecologic Cancer.

[32]  C. Wheeler,et al.  Viral Determinants of Human Papillomavirus Persistence following Loop Electrical Excision Procedure Treatment for Cervical Intraepithelial Neoplasia Grade 2 or 3 , 2007, Cancer Epidemiology Biomarkers & Prevention.

[33]  E. Campo,et al.  Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. , 2006, Gynecologic oncology.

[34]  T. Kucera,et al.  Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.

[35]  C. Wheeler,et al.  Human Papillomavirus Testing Following Loop Electrosurgical Excision Procedure Identifies Women at Risk for Posttreatment Cervical Intraepithelial Neoplasia Grade 2 or 3 Disease , 2006, Cancer Epidemiology Biomarkers & Prevention.

[36]  L. Mariani,et al.  Relationship of Up-Regulation of 67-kd Laminin Receptor to Grade of Cervical Intraepithelial Neoplasia and to High-Risk HPV Types and Prognosis in Cervical Cancer , 2006, Acta Cytologica.

[37]  M. Poljak,et al.  Efficiency of three surgical procedures in eliminating high-risk human papillomavirus infection in women with precancerous cervical lesions. , 2006, European journal of gynaecological oncology.

[38]  N. Brink,et al.  The impact of high risk human papillomavirus testing in an inner London colposcopy clinic , 2005, Journal of medical virology.

[39]  M. Spitzer,et al.  The Role Treatment for Cervical Intraepithelial Neoplasia Plays in the Disappearance of Human Papilloma Virus , 2005, Journal of lower genital tract disease.

[40]  L. Sarian,et al.  Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[41]  R. Rosales,et al.  Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. , 2004, Human gene therapy.

[42]  K. Ohama,et al.  Human papillomavirus DNA status after loop excision for cervical intraepithelial neoplasia grade III - A prospective study. , 2004, International journal of molecular medicine.

[43]  S. Yamaguchi,et al.  Eradication and reinfection of human papillomavirus after photodynamic therapy for cervical intraepithelial neoplasia , 2003, International Journal of Clinical Oncology.

[44]  D. Vinatier,et al.  Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. , 2003, Gynecologic oncology.

[45]  A. Kubin,et al.  Cold-knife conization versus photodynamic therapy with topical 5-aminolevulinic acid (5-ALA) in cervical intraepithelial neoplasia (CIN) II with associated human papillomavirus infection: a comparison of preliminary results. , 2003, Anticancer research.

[46]  Eileen M. Burd,et al.  Human Papillomavirus and Cervical Cancer , 1988, The Lancet.

[47]  W. Quint,et al.  The role of genotype‐specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia , 2002, International journal of cancer.

[48]  O. Kimberger,et al.  Is therapeutic conization sufficient to eliminate a high-risk HPV infection of the uterine cervix? A clinicopathological analysis. , 2002, Anticancer research.

[49]  J. Dillner,et al.  Rate of Human Papillomavirus Clearance After Treatment of Cervical Intraepithelial Neoplasia , 2002, Obstetrics and gynecology.

[50]  L. Smart,et al.  Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia , 2002, BJOG : an international journal of obstetrics and gynaecology.

[51]  S. Hsueh,et al.  Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. , 2001, American journal of obstetrics and gynecology.

[52]  C. Meijer,et al.  Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia , 2001, British Journal of Cancer.

[53]  B. Mol,et al.  Prediction of recurrent and residual cervical dysplasia by human papillomavirus detection among patients with abnormal cytology. , 1999, Gynecologic oncology.

[54]  A. Teyssié,et al.  Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. , 1998, Infectious diseases in obstetrics and gynecology.

[55]  B. Mol,et al.  Clearance of Cervical Human Papillomavirus Infection by Treatment for Cervical Dysplasia , 1997, Sexually transmitted diseases.

[56]  B. Mol,et al.  Human papillomavirus DNA after treatment of cervical dysplasia: Low prevalence in normal cytologic smears , 1996, Cancer.

[57]  J. Dillner,et al.  Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. , 1996, American journal of obstetrics and gynecology.

[58]  V. Moreno,et al.  Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective , 1995 .

[59]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[60]  E. Piccione,et al.  Efficacy of CO2 laser surgery in treating squamous intraepithelial lesions. An analysis of clinical and virologic results. , 1994, The Journal of reproductive medicine.